Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Stefan Bjelosevic, Ph.D.

Title
Institution
Department
Address
Profile Picture

Biography
Peter MacCallum Cancer Centre & University of Melbourne, Melbourne, AustraliaPhD2021Hematology/Oncology, Cancer Biology
University of Melbourne, Melbourne, AustraliaBSc (Hons)2016Pathology
2022
The University of Melbourne Chancellor’s Prize for Best PhD Thesis (Nominated)
2022
Regeneron Scholars Program
2021 - 2022
Cancer Council Victoria Postdoctoral Cancer Research Fellowship
2020
Victorian Comprehensive Cancer Centre (VCCC) Picchi Award for Excellence in Cancer Research
2020
Keystone Symposia Future of Science Fund Scholarship
2020
European Haematology Association (EHA) Travel Grant
2020
International Society for Experimental Haematology (ISEH) Travel Grant
2017 - 2020
Australian Government Research Training Program Scholarship
2017 - 2020
Robert Kirby Peter MacCallum Foundation Post Graduate Award
2010 - 2013
Kwong Lee Dow Young Scholar

Overview
I am a Research Fellow in Pediatrics in the Department of Pediatric Oncology at Dana-Farber Cancer Institute, with co-appointments at Harvard Medical School and The Broad Institute of MIT and Harvard, based in Boston, MA. My research is centered on pediatric hematological malignancies, and the discovery of new cancer targets and small-molecule therapeutic leads in the laboratory of Professor Kimberly Stegmaier (Vice Chair of Pediatric Oncology Research and Co-Director, Pediatric Hematologic Malignancy Program, Dana-Farber Cancer Institute and Boston Children's Hospital).

I received my doctorate under the mentorship of Professor Ricky Johnstone (Executive Director of Cancer Research) and Dr Gareth Gregory at the Peter MacCallum Cancer Centre and The Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, Australia. My doctoral work focussed on dissecting metabolic rewiring mediated by FLT3-ITD, one of the most common mutations in acute myeloid leukemia (AML), and uncovered a targetable dependency in this aggressive subset of AML. This work was published in the top journal Cancer Discovery in 2021.

My postdoctoral work builds on my previous training by extending my expertise in AML model generation and characterization, large-scale genetic screening, transcription, epigenetics, cellular metabolism, and use of in vivo models for therapeutic validation.

Featured Content

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Salmon JM, Todorovski I, Stanley KL, Bruedigam C, Kearney CJ, Martelotto LG, Rossello F, Semple T, Arnau GM, Zethoven M, Bots M, Bjelosevic S, Cluse LA, Fraser PJ, Litalien V, Vidacs E, McArthur K, Matthews AY, Gressier E, de Weerd NA, Lichte J, Kelly MJ, Hogg SJ, Hertzog PJ, Kats LM, Vervoort SJ, De Carvalho DD, Scheu S, Bedoui S, Kile BT, Lane SW, Perkins AC, Wei AH, Dominguez PM, Johnstone RW. Epigenetic Activation of Plasmacytoid DCs Drives IFNAR-Dependent Therapeutic Differentiation of AML. Cancer Discov. 2022 06 02; 12(6):1560-1579. PMID: 35311997; PMCID: PMC9355625.
    Citations: 1     Fields:    Translation:HumansCells
  2. Xiao L, Karsa M, Ronca E, Bongers A, Kosciolek A, El-Ayoubi A, Revalde JL, Seneviratne JA, Cheung BB, Cheung LC, Kotecha RS, Newbold A, Bjelosevic S, Arndt GM, Lock RB, Johnstone RW, Gudkov AV, Gurova KV, Haber M, Norris MD, Henderson MJ, Somers K. The Combination of Curaxin CBL0137 and Histone Deacetylase Inhibitor Panobinostat Delays KMT2A-Rearranged Leukemia Progression. Front Oncol. 2022; 12:863329. PMID: 35677155; PMCID: PMC9168530.
    Citations: 1     
  3. Brown LM, Hediyeh-Zadeh S, Sadras T, Huckstep H, Sandow JJ, Bartolo RC, Kosasih HJ, Davidson NM, Schmidt B, Bjelosevic S, Johnstone R, Webb AI, Khaw SL, Oshlack A, Davis MJ, Ekert PG. SFPQ-ABL1 and BCR-ABL1 use different signaling networks to drive B-cell acute lymphoblastic leukemia. Blood Adv. 2022 04 12; 6(7):2373-2387. PMID: 35061886; PMCID: PMC9006296.
    Citations:    Fields:    Translation:HumansCells
  4. Hogg SJ, Motorna O, Cluse LA, Johanson TM, Coughlan HD, Raviram R, Myers RM, Costacurta M, Todorovski I, Pijpers L, Bjelosevic S, Williams T, Huskins SN, Kearney CJ, Devlin JR, Fan Z, Jabbari JS, Martin BP, Fareh M, Kelly MJ, Dupéré-Richer D, Sandow JJ, Feran B, Knight D, Khong T, Spencer A, Harrison SJ, Gregory G, Wickramasinghe VO, Webb AI, Taberlay PC, Bromberg KD, Lai A, Papenfuss AT, Smyth GK, Allan RS, Licht JD, Landau DA, Abdel-Wahab O, Shortt J, Vervoort SJ, Johnstone RW. Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300/CBP inhibition. Mol Cell. 2021 05 20; 81(10):2183-2200.e13. PMID: 34019788; PMCID: PMC8183601.
    Citations: 16     Fields:    Translation:HumansCells
  5. Vervoort SJ, Welsh SA, Devlin JR, Barbieri E, Knight DA, Offley S, Bjelosevic S, Costacurta M, Todorovski I, Kearney CJ, Sandow JJ, Fan Z, Blyth B, McLeod V, Vissers JHA, Pavic K, Martin BP, Gregory G, Demosthenous E, Zethoven M, Kong IY, Hawkins ED, Hogg SJ, Kelly MJ, Newbold A, Simpson KJ, Kauko O, Harvey KF, Ohlmeyer M, Westermarck J, Gray N, Gardini A, Johnstone RW. The PP2A-Integrator-CDK9 axis fine-tunes transcription and can be targeted therapeutically in cancer. Cell. 2021 06 10; 184(12):3143-3162.e32. PMID: 34004147; PMCID: PMC8567840.
    Citations: 17     Fields:    Translation:HumansAnimalsCells
  6. Bjelosevic S, Gruber E, Newbold A, Shembrey C, Devlin JR, Hogg SJ, Kats L, Todorovski I, Fan Z, Abrehart TC, Pomilio G, Wei A, Gregory GP, Vervoort SJ, Brown KK, Johnstone RW. Serine Biosynthesis Is a Metabolic Vulnerability in FLT3-ITD-Driven Acute Myeloid Leukemia. Cancer Discov. 2021 06; 11(6):1582-1599. PMID: 33436370.
    Citations: 10     Fields:    Translation:HumansAnimalsCells
  7. Kosasih HJ, Davidson NM, Bjelosevic S, Morrish E, Brennan MS, Oshlack A, Johnstone RW, Brumatti G, Khaw SL, Ekert PG. MLL-TFE3: a novel and aggressive KMT2A fusion identified in infant leukemia. Blood Adv. 2020 10 13; 4(19):4918-4923. PMID: 33035331; PMCID: PMC7556123.
    Citations:    Fields:    Translation:Humans
  8. Siekmann I, Bjelosevic S, Landman K, Monagle P, Ignjatovic V, Crampin EJ. Mathematical modelling indicates that lower activity of the haemostatic system in neonates is primarily due to lower prothrombin concentration. Sci Rep. 2019 03 08; 9(1):3936. PMID: 30850652; PMCID: PMC6408458.
    Citations: 1     Fields:    Translation:Humans
  9. Lugones M, Parkin G, Bjelosevic S, Takagi M, Clarke C, Anderson V, Ignjatovic V. Blood biomarkers in paediatric mild traumatic brain injury: a systematic review. Neurosci Biobehav Rev. 2018 04; 87:206-217. PMID: 29462640.
    Citations: 8     Fields:    Translation:Humans
  10. Bjelosevic S, Pascovici D, Ping H, Karlaftis V, Zaw T, Song X, Molloy MP, Monagle P, Ignjatovic V. Quantitative Age-specific Variability of Plasma Proteins in Healthy Neonates, Children and Adults. Mol Cell Proteomics. 2017 05; 16(5):924-935. PMID: 28336724; PMCID: PMC5417830.
    Citations: 15     Fields:    Translation:HumansCells
  11. Bjelosevic S, Ignjatovic V. Unravelling age-specific differences in the human proteome and the implications for medicine. Expert Rev Proteomics. 2017 04; 14(4):281-283. PMID: 28276749.
    Citations:    Fields:    Translation:HumansAnimals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Bjelosevic's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (79)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.